Nuvation Bio Inc.
6.52USD
-0.0900 (-1.36%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | — | 0.0 | 7.9M | 62.9M | 199.1M | 282.4M |
| Q1 | — | — | 0.0 | 3.1M | 83.2M | — |
| Q2 | — | 0.0 | 1.4M | 4.8M | 31.7M | — |
| Q3 | — | 0.0 | 727.0K | 13.1M | 35.8M | — |
| Q4 | — | 0.0* | 5.7M* | 41.9M* | 48.5M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.480 | -.350 | -2.11 | -.600 | -.290 | -.015 |
| Q1 | -.100 | -.100 | -.070 | -.160 | .010 | — |
| Q2 | -.160 | -.090 | -1.89 | -.170 | -.180 | — |
| Q3 | -.120 | -.090 | -.150 | -.160 | -.090 | — |
| Q4 | -96.18* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -62.99* |
| -183.97* |
| -107.14* |
| -.090 |
| — |